World Health Organization

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Bulat Utemuratov Foundation supports World Autism Awareness Day with initiatives across Kazakhstan

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Health, Growth, Disease, Spectrum, Welfare, Quality of life, City, World Health Organization, Social skills, Social, Parent, ASD, Vaccine

ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.

Key Points: 
  • ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.
  • Over the month of April, the Foundation's Asyl Miras Autism Centers, which operate in 12 cities across Kazakhstan, will hold open days to educate visitors about ASD.
  • Marat Aitmagambetov, Director of the Bulat Utemuratov Foundation said, "In recent years we have seen an increase in parents requesting autism diagnostic consultations for their children.
  • Effective ASD management can significantly improve the social skills of children with the condition, and the Foundation remains committed to supporting Kazakhstanis with autism.

Bulat Utemuratov Foundation supports World Autism Awareness Day with initiatives across Kazakhstan

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Health, Growth, Disease, Spectrum, Welfare, Quality of life, City, World Health Organization, Social skills, Social, Parent, ASD, Vaccine

ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.

Key Points: 
  • ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.
  • Over the month of April, the Foundation's Asyl Miras Autism Centers, which operate in 12 cities across Kazakhstan, will hold open days to educate visitors about ASD.
  • Marat Aitmagambetov, Director of the Bulat Utemuratov Foundation said, "In recent years we have seen an increase in parents requesting autism diagnostic consultations for their children.
  • Effective ASD management can significantly improve the social skills of children with the condition, and the Foundation remains committed to supporting Kazakhstanis with autism.

ASEAN+3 Policymakers Should Rebuild Policy Space and Address Long-term Challenges Amid Positive Outlook

Retrieved on: 
Monday, April 8, 2024
Synthetic media, Social, Longevity, Growth, AMRO, Intelligence, COVID-19, FDI, Policy, Ageing, World Health Organization, PDR, Tourism, Generative

AMRO staff now forecast the ASEAN+3 region to grow at 4.5 percent this year, up from 4.3 percent in 2023.

Key Points: 
  • AMRO staff now forecast the ASEAN+3 region to grow at 4.5 percent this year, up from 4.3 percent in 2023.
  • The anticipated turnaround in exports, in part due to the global chips upcycle, and the continued recovery of tourism will provide additional tailwinds.
  • Nevertheless, AMRO warns against taking the region's positive momentum for granted in light of potential disruptors to the growth trajectory.
  • "Now that the current outlook is quite positive, given robust growth and gradual disinflation, ASEAN+3 economies need to rebuild policy space as much as they can."

ASEAN+3 Policymakers Should Rebuild Policy Space and Address Long-term Challenges Amid Positive Outlook

Retrieved on: 
Monday, April 8, 2024
Synthetic media, Social, Longevity, Growth, AMRO, Intelligence, COVID-19, FDI, Policy, Ageing, World Health Organization, PDR, Tourism, Multimedia, Generative

AMRO staff now forecast the ASEAN+3 region to grow at 4.5 percent this year, up from 4.3 percent in 2023.

Key Points: 
  • AMRO staff now forecast the ASEAN+3 region to grow at 4.5 percent this year, up from 4.3 percent in 2023.
  • The anticipated turnaround in exports, in part due to the global chips upcycle, and the continued recovery of tourism will provide additional tailwinds.
  • Nevertheless, AMRO warns against taking the region's positive momentum for granted in light of potential disruptors to the growth trajectory.
  • "Now that the current outlook is quite positive, given robust growth and gradual disinflation, ASEAN+3 economies need to rebuild policy space as much as they can."

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Retrieved on: 
Monday, March 18, 2024
Survival, JCO, Caregiver, Therapy, Palliative care, Patient, Ethics, Journal, Mouse, Research, Hebrew University of Jerusalem, Anxiety, MD, Nature, Quality of life, Adjustment disorder, World Health Organization, Adjustment, ASCO, Molecular Psychiatry, WHO, Paper, FDA, PBM

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:PBM) ("Psyence Biomed" or the "Company") today issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin.

Key Points: 
  • The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog.
  • “Neuroplasticity” is increasingly recognized as the gold standard by which the therapeutic efficacy of psychedelic pharmaceutical medicines can be measured.
  • The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.
  • Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Inflammasome, Obesity, Entrepreneurship, Multiple sclerosis, Inflammation, Death, NLRP3, World Health Organization, ASC, Therapy, Atherosclerosis, Drug development, Pharmaceutical industry

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.

Key Points: 
  • According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.
  • WESTON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in a panel discussion titled “Inflammation Illuminated,” at Benzinga’s Virtual Healthcare Summit 2024.
  • He will also address new innovations in drug development to alleviate damaging inflammation.
  • Details regarding Mr. Glover’s panel discussion are as follows:

Merck Continues the Fight against Schistosomiasis in a Storytelling Lab

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Other Health, Other Education, Health, Pharmaceutical, General Health, Science, Education, Parasitism, Schistosomiasis, Disease, Tablet, SVP, Male, Health education, World Health Organization, Skin, Neglected tropical diseases, WHO, Multimedia, Ministry, Pharmaceutical industry

Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.

Key Points: 
  • Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.
  • This innovative initiative aims to develop creative solutions in order to raise awareness about schistosomiasis and, in doing so, bring about behavioral change.
  • View the full release here: https://www.businesswire.com/news/home/20240402803315/en/
    The winners of this year's Merck Bilharzia Storytelling Lab in Ethiopia (Photo: Business Wire)
    Schistosomiasis is one of the most prevalent parasitic diseases and affects more than 240 million people worldwide.
  • Read more about how Merck is committed to eliminating schistosomiasis: www.merckgroup.com/schistosomiasis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240402803315/en/

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.